Press release

Besançon, France – March 31st, 2021 – MED’INN’PHARMA participates to 3rd step of the French Bioproduction Tour held in Besançon. With other local biotech, MIP will discuss about the local environment and means dedicated to the bioproduction field in order to innovate in term of technology and new drug candidates. This step is part of a National tour initiated to describe and emphasize bioproduction local fields and private companies and academics, and favor interactions and collaborations between actors to emphasize French Bioproduction.31

Vidéo: 3rd French Bioprod Tour

Program: program polemicrotechniques

About MED’INN’PHARMA – MIP, a French pharma biotechnology company funded in 2017, is a leader in the development of bio-identic drugs with pro-resolutive properties for the treatment of acute and chronic inflammatory situations. MIP’ first-in-class proprietary therapeutic lead candidates have the potential for broad applications in Immunology, infectious diseases, pulmonary, neuroscience, cardiology, metabolic and regenerative medicines. The company develops SuperMApo bio-identic drug candidate (license granted by INSERM-EFS-UBFC) with high pro-resolutive properties through a deep reeducation of the whole immune system.